AMENDED AND RESTATED SERVICES AGREEMENTServices Agreement • February 9th, 2016 • Axovant Sciences Ltd. • Pharmaceutical preparations • New York
This Amended and Restated Services Agreement (the “Agreement”) is entered into effective as of October 13, 2015 (the “Effective Date”), by and between Roivant Sciences, Inc., a corporation organized under the laws of the State of Delaware (“Service Provider”), Axovant Sciences Ltd. (f/k/a Roivant Neurosciences Ltd.), an exempted limited company organized under the laws of the country of Bermuda (“RNL”), and Axovant Sciences, Inc. (f/k/a Roivant Neurosciences, Inc.), a corporation organized under the laws of the State of Delaware and a wholly owned subsidiary of RNL (“RNI”, and together with RNL, the “Service Recipients” and each a “Service Recipient”).
Development, Marketing and Supply Agreement by and between Arena Pharmaceuticals GmbH and Roivant Sciences Ltd. dated May 8, 2015Development, Marketing and Supply Agreement • February 9th, 2016 • Axovant Sciences Ltd. • Pharmaceutical preparations • New York
This Development, Marketing and Supply Agreement (the “Agreement”) is made and entered into as of May 8, 2015 (the “Effective Date”) by and between Arena Pharmaceuticals GmbH, a company organized under the laws of Switzerland having a principal place of business at Untere Brühlstrasse 4, 4800, Zofingen, Switzerland (“Arena”), and Roivant Sciences Ltd., a Bermuda Exempted Limited Company having a principal place of business at 2 Clarendon House, Hamilton HM11, Bermuda (“Roivant”). Each of Arena and Roivant may be referred to in this Agreement individually as a “Party” and collectively as the “Parties”.
